The present invention relates to methods of detecting CD200L in a female subject from a secretory phase biological sample. Increased levels of CD200L have been determined to be associated with endometriosis. CD200L is therefore a useful biomarker for the diagnosis of endometriosis and a useful target for therapeutic intervention.

The present disclosure provides methods and systems for generating a reproductive hormone profile of a subject. A method for generating a reproductive hormone profile of a subject may comprise (a) obtaining a hair sample of the subject; (b) processing the hair sample to generate data indicative of a presence of a reproductive hormone in the hair sample; and (c) processing at least some of the data of (b) using a reproductive hormone classifier to generate the reproductive hormone of the subject. The present disclosure also provides compositions and kits for performing methods described herein or using the systems described herein.

Described herein are improved methods for the detection of endometriosis. Generally, the methods include, but are not limited to, applying machine learning algorithm to miRNA levels in order to detect, predict, diagnose, or monitor the presence or absence of endometriosis.

The present invention relates to methods and compositions for differentiating between absence of disease, endometriosis, and EAOC or serous ovarian cancer in a subject. It is based, at least in part, on the discovery that certain microRNAs are associated with each of these conditions.

The present invention is a cytocidal agent including a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 and a site selectively binding to a target molecule, in which the peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 is a peptide exclusively consisting of L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to the 14 amino acids are D-amino acids, and the 15.sup.th to 19.sup.th amino acids are L-amino acids, a peptide in which, in amino acid sequences represented by SEQ ID NO: 1, the first to 14.sup.th amino acids are L-amino acids, and the 15.sup.th to the 1.9.sup.th amino acids are D-amino acids, or a peptide exclusively consisting of D-amino acids.

The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.

In some aspects, the disclosure relates to methods for screening clinical samples for the presence of L-form bacteria associated with endometriosis and/or ovarian fibroid tumors. The disclosure is based, in part, on screening methods used to diagnose a subject as likely having or likely not having endometriosis and/or an ovarian fibroid tumor. In some embodiments, the disclosure relates to methods of treating endometriosis by administering an antibiotic to a subject that has been determined to be infected by one or more strains of L-form bacteria.

The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.

Methods and compositions are provided for treating endometriosis in an individual, and the pain associated with endometriosis. Aspects of the methods include administering to the individual an agent that promotes ALDH activity.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis and in particular early stages to methods of selecting a patient for therapy and to methods for monitoring disease progression in a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of PSP94 in a sample of the patient, and comparing the determined amount or concentration to a reference.